Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
04/24/15

Data Presentations at 2015 ECCMID Conference Highlight Key Findings in Light of the Growing Global Threat of Antibiotic Resistance

04/16/15

Poster Presentations Provide Further Support for Role of VIBATIV(R) in Fight Against Antibiotic Resistance

04/07/15
GEORGE TOWN, GRAND CAYMAN -- ( Marketwired ) -- 04/07/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer, is scheduled to present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 , at 8:00 a.m. EDT .
04/02/15
GEORGE TOWN, GRAND CAYMAN -- ( Marketwired ) -- 04/02/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced today that stock options to purchase an aggregate of 45,700 of the Company's ordinary shares were granted to six new non-executive officer
03/12/15
GEORGE TOWN, GRAND CAYMAN -- ( Marketwired ) -- 03/12/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the initiation of a Phase 2b study of velusetrag (TD-5108), an investigational drug for the treatment of patients with gastroparesis and
03/10/15

VIBATIV(R) (Telavancin) Commercial Team Expanded in Target Geographies, Registry Study Initiated and Telavancin Phase 3 Bacteremia Study Underway; Pipeline Progressing; TD-4208 Advancing to Phase 3 Registrational Program, and Partnered With Mylan in Broad Development and Commercialization Collaboration

03/04/15
GEORGE TOWN, CAYMAN ISLANDS -- ( Marketwired ) -- 03/04/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (the "Company") announced today that stock options to purchase an aggregate of 10,500 of the Company's ordinary shares were granted to three new non-executive officer employees on March 2, 2015 .
03/03/15
GEORGE TOWN, GRAND CAYMAN -- ( Marketwired ) -- 03/03/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended December 31, 2014 after market close on Tuesday, March 10, 2015 .
02/24/15

Trial Designed to Support Regulatory Filing; Potential to Expand Label for VIBATIV(R) (telavancin) to Third Difficult-to-Treat, Gram-Positive Infection Type

02/10/15

First Patient Enrolled in Telavancin Observational Use Registry (TOUR); Large-Scale Study to Create Knowledge Base to Guide Optimal Clinical Use and Future Development of VIBATIV(R)